A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Corporation
Start Date
April 19, 2017
End Date
March 31, 2020
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Boehringer Ingelheim Corporation
Start Date
April 19, 2017
End Date
March 31, 2020